365 related articles for article (PubMed ID: 25473151)
21. Management of recurrent hepatitis C virus after liver transplantation.
Jiménez-Pérez M; González-Grande R; Rando-Muñoz FJ
World J Gastroenterol; 2014 Nov; 20(44):16409-17. PubMed ID: 25469009
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis C virus relies on lipoproteins for its life cycle.
Grassi G; Di Caprio G; Fimia GM; Ippolito G; Tripodi M; Alonzi T
World J Gastroenterol; 2016 Feb; 22(6):1953-65. PubMed ID: 26877603
[TBL] [Abstract][Full Text] [Related]
23. Ribavirin induced hemolysis: a novel mechanism of action against chronic hepatitis C virus infection.
Soota K; Maliakkal B
World J Gastroenterol; 2014 Nov; 20(43):16184-90. PubMed ID: 25473172
[TBL] [Abstract][Full Text] [Related]
24. Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein.
Hung TC; Jassey A; Liu CH; Lin CJ; Lin CC; Wong SH; Wang JY; Yen MH; Lin LT
Phytomedicine; 2019 Feb; 53():62-69. PubMed ID: 30668413
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis C virus and natural compounds: a new antiviral approach?
Calland N; Dubuisson J; Rouillé Y; Séron K
Viruses; 2012 Oct; 4(10):2197-217. PubMed ID: 23202460
[TBL] [Abstract][Full Text] [Related]
26. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.
Haberstroh A; Schnober EK; Zeisel MB; Carolla P; Barth H; Blum HE; Cosset FL; Koutsoudakis G; Bartenschlager R; Union A; Depla E; Owsianka A; Patel AH; Schuster C; Stoll-Keller F; Doffoël M; Dreux M; Baumert TF
Gastroenterology; 2008 Nov; 135(5):1719-1728.e1. PubMed ID: 18718838
[TBL] [Abstract][Full Text] [Related]
27. Entry inhibitors: New advances in HCV treatment.
Qian XJ; Zhu YZ; Zhao P; Qi ZT
Emerg Microbes Infect; 2016 Jan; 5(1):e3. PubMed ID: 26733381
[TBL] [Abstract][Full Text] [Related]
28. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy.
Bader el-Din NG; Abd el-Meguid M; Tabll AA; Anany MA; Esmat G; Zayed N; Helmy A; el-Zayady AR; Barakat A; el-Awady MK
J Gastroenterol Hepatol; 2011 Jan; 26(1):55-62. PubMed ID: 21175794
[TBL] [Abstract][Full Text] [Related]
29. Entry inhibitors and future treatment of hepatitis C.
Fofana I; Jilg N; Chung RT; Baumert TF
Antiviral Res; 2014 Apr; 104():136-42. PubMed ID: 24525381
[TBL] [Abstract][Full Text] [Related]
30. Virus-Specific CD4+ T Cells Have Functional and Phenotypic Characteristics of Follicular T-Helper Cells in Patients With Acute and Chronic HCV Infections.
Raziorrouh B; Sacher K; Tawar RG; Emmerich F; Neumann-Haefelin C; Baumert TF; Thimme R; Boettler T
Gastroenterology; 2016 Mar; 150(3):696-706.e3. PubMed ID: 26584604
[TBL] [Abstract][Full Text] [Related]
31. Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence.
Korda D; Lenard ZM; Gerlei Z; Jakab Z; Haboub-Sandil A; Wagner L; Varga M; Cseprekal O; Marton A; Horvathy D; Takacs S; Doros A; Mathe Z
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):27-32. PubMed ID: 29049126
[TBL] [Abstract][Full Text] [Related]
32. Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.
Pedersen J; Jensen TB; Carlsen TH; Schønning K; Christensen PB; Laursen AL; Krarup H; Bukh J; Weis N
PLoS One; 2013; 8(5):e62674. PubMed ID: 23667506
[TBL] [Abstract][Full Text] [Related]
33. Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation.
Rowe IA; Tully DC; Armstrong MJ; Parker R; Guo K; Barton D; Morse GD; Venuto CS; Ogilvie CB; Hedegaard DL; McKelvy JF; Wong-Staal F; Allen TM; Balfe P; McKeating JA; Mutimer DJ
Liver Transpl; 2016 Mar; 22(3):287-97. PubMed ID: 26437376
[TBL] [Abstract][Full Text] [Related]
34. An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission.
Tarr AW; Lafaye P; Meredith L; Damier-Piolle L; Urbanowicz RA; Meola A; Jestin JL; Brown RJ; McKeating JA; Rey FA; Ball JK; Krey T
Hepatology; 2013 Sep; 58(3):932-9. PubMed ID: 23553604
[TBL] [Abstract][Full Text] [Related]
35. Liver Transplant From Increased-Risk Donors in the Era of Direct-Acting Antivirals for Hepatitis C.
Shaikh OS; Rogal S; Malik A; Sharma V; Cacciarelli T
Exp Clin Transplant; 2020 Oct; 18(5):605-611. PubMed ID: 31324136
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents?
Dall'Agata M; Gramenzi A; Biselli M; Bernardi M
World J Gastroenterol; 2014 Jul; 20(28):9253-60. PubMed ID: 25071318
[TBL] [Abstract][Full Text] [Related]
38. Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients.
Ueda Y; Uemoto S
Transplantation; 2016 Jan; 100(1):54-60. PubMed ID: 26335914
[TBL] [Abstract][Full Text] [Related]
39. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
40. Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation.
Guillouche P; Féray C
Aliment Pharmacol Ther; 2011 Jan; 33(2):163-74. PubMed ID: 21083593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
